Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +15

<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers

Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou et al. · Journal of Clinical Oncology · 2012 · 1.6K citations · Full text

Medicine, Molecular Biology, Oncology +16

<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi Koivunen, Craig H. Mermel, Kreshnik Zejnullahu et al. · Clinical Cancer Research · 2008 · 983 citations · Full text

Medicine, Oncology, Pharmacology +17

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

J. Jean Cui, Michelle Tran‐Dubé, Hong Shen et al. · Journal of Medicinal Chemistry · 2011 · 922 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 750 citations · Full text

Medicine, Medicinal Chemistry, Oncology +16